Soleno Therapeutics (SLNO) Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Go back to Soleno Therapeutics (SLNO) Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

May 4, 2021 8:00 AM EDT

Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR

Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the presentation of positive behavioral outcomes data from the Companys ongoing open-label extension study (C602) of DCCR (diazoxide choline) Extended-Release tablets for patients with Prader-Willi Syndrome (PWS), at the Pediatric Academic Societies (PAS) 2021... More